Lung Cancer in the COVID-19 Era
The global COVID-19 pandemic has forced the medical community to reexamine every aspect of healthcare delivery. Patients with cancer, particularly lung cancer, are a vulnerable population and may be more prone to coronavirus infection or complications from infection. While our understanding of the relevant biology is still unfolding, immediate efforts to modify therapeutic strategies for patients with lung cancer are critical to mitigating patient risk. This can involve reducing visits to cancer centers, using alternate systemic agents felt to reduce risk, or altering the overall multidisciplinary approach. During times when peak infection may reduce available resources, innovative strategies will be born of necessity. This research topic explores potential approaches to managing patients with lung cancer in the COVID-19 era.
A standard EDITORIAL TRACKING SYSTEM is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.imedpub.com/submissions/biology-medical-research.html) or forwarded to the Editorial Office at email@example.com
Journal of Biology and Medical Research
For Queries Contact: +1-504-608-2390